Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

An experimental model of clinical immunity for human malaria

Hou MM. et al, (2025)

Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in children.

Natama HM. et al, (2024), Lancet Infect Dis

Malaria: Past, Present and Future.

Salkeld J. et al, (2024), Clin Med (Lond)

Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled phase 2b trial in children

Natama HM. et al, (2024)

Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies.

King LDW. et al, (2024), Cell Rep Med, 5

Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial.

Silk SE. et al, (2024), Lancet Infect Dis

Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development.

Mertens JE. et al, (2024), Vaccine, 42, 3621 - 3629

First Phase 1b, single-center, age de-escalation trial of theP. falciparumblood-stage malaria vaccine candidate RH5.1/Matrix-M™: a delayed boost regimen induces high levels of functional antibodies in 5-17 month old Tanzanian infants

Silk SE. et al, (2024)

Evaluation of Precision of thePlasmodium knowlesiGrowth Inhibition Assay forPlasmodium vivaxDuffy-Binding Protein-based Malaria Vaccine Development

Mertens JE. et al, (2024)

PvDBPII elicits multiple antibody-mediated mechanisms that reduce growth in a Plasmodium vivax challenge trial.

Martinez FJ. et al, (2024), NPJ Vaccines, 9

Preclinical Development of a Stabilized RH5 Virus-Like Particle Vaccine that Induces Improved Anti-Malarial Antibodies

King LDW. et al, (2024)

Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5

Wang LT. et al, (2023)

Analysis of the Diverse Antigenic Landscape of the Malaria Invasion Protein RH5 Identifies a Potent Vaccine-Induced Human Public Antibody Clonotype

Barrett JR. et al, (2023)

Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.

Kelly E. et al, (2023), J Infect, 87, 230 - 241

A systematic analysis of the human immune response to Plasmodium vivax.

Bach FA. et al, (2023), J Clin Invest

Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults.

Silk SE. et al, (2023), Med

PvDBPII-Matrix M elicits polyfunctional antibodies that limit parasite growth in a challenge trial

Martinez FJ. et al, (2023)

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.

Liu X. et al, (2023), J Infect, 87, 18 - 26

Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection

Hou M. et al, (2023), Science Translational Medicine

Assessment of precision in growth inhibition assay (GIA) using human anti-PfRH5 antibodies.

Miura K. et al, (2023), Malar J, 22

Load More

1
2
3
4
5

Include forthcoming?